UCB stock adds AI antibody research partnership with Cradle
Published on 11/04/2026 at 11:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSUCB expands AI drug research
- UCB and Cradle will apply AI-based protein design to selected antibody research programs.
- The collaboration covers discovery, lead optimization and preparation for preclinical development.
- UCB’s next scheduled full-year results and 2027 guidance are due on February 25, 2027.
UCB and Cradle announced a strategic collaboration on Wednesday, November 4, 2026, to use artificial intelligence in the design and engineering of antibodies. The announcement was made from Brussels and Amsterdam and was reported by Ideal Investisseur.
UCB will use Cradle’s AI-based protein design platform in selected research projects. The planned work covers the full early development chain, from identifying active molecules to optimizing lead candidates and preparing them for preclinical development.
AI enters the discovery workflow
The partnership is built around a recurring exchange between predictive models and laboratory experiments. Results from UCB’s experiments will feed program-specific models, creating what the companies describe as a lab-in-the-loop process. The objective is to help researchers assess and improve candidates more quickly while retaining laboratory validation as a central step.
Alistair Henry, UCB’s chief scientific officer, said the company views AI as a force multiplier for scientific expertise rather than an end in itself. He said combining predictive modeling with laboratory work could help researchers design better molecules and learn faster. Stef van Grieken, Cradle’s chief executive and co-founder, said the platform is intended to support broader use across programs, modalities and complex engineering challenges.
Potential impact remains long term
The agreement strengthens UCB’s technology base in biologics research, but the announcement does not identify a clinical candidate, development milestone or commercial revenue contribution. Any financial impact therefore depends on whether the collaboration produces viable drug candidates and advances them through later development stages.
The move comes as UCB focuses on medicines for serious immune-system and central-nervous-system diseases. The company’s 2026 outlook has also highlighted commercial momentum in BIMZELX and CIMZIA, while the next scheduled full-year results and formal 2027 guidance are due on February 25, 2027, according to the report.
UCB stock traded at 279.30 euros on Lang & Schwarz at 11:41 CET on Wednesday, November 4, 2026. Investors can follow the real-time quote of UCB stock.
UCB company facts
- Company: UCB S.A.
- ISIN: BE0003739530
- Primary listing: Euronext Brussels
- Lang & Schwarz quote: 279.30 euros at 11:41 CET on November 4, 2026
Investors can follow broader European market coverage in the current market reports.
More developments are available in more news and analyses on UCB stock.
